ArticleFrontiers in immunology2026
Physicochemical convergence in antibody CDR3-VH repertoires recognizing phosphorothioate-modified oligonucleotides backbone.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The development of recombinant antibody binders against phosphorothioate-modified antisense oligonucleotides (PS-ASOs) remains challenging due to the highly polyanionic character and structural flexibility of the phosphorothioate backbone. Here, we applied a next-generation sequencing (NGS)-guided phage display strategy to determine whether selection against PS-modified ASOs induces reproducible repertoire remodeling and the emergence of shared CDR3 physicochemical signatures associated with PS-ASO recognition. Methods: Two independent two-round phage display biopanning strategies against biotinylated PS-ASO targets were coupled to targeted amplicon sequencing of VH and VL FR3-CDR3-FR4 regions on the Illumina MiSeq platform. CDR3 clonotypes were reconstructed using a dedicated bioinformatic pipeline including quality filtering, read merging, in-frame translation, clonotype counting, CPM normalization, enrichment analysis, and physicochemical descriptor profiling. Representative enriched scFv clones were further evaluated by ELISA-based binding and competition assays and by fluorescence microscopy in ASO-treated cells. Results: Deep sequencing revealed a marked reduction in repertoire diversity from Round 1 to Round 2, associated with reproducible clonal dominance across independent selection strategies. These changes were already evident at early stages of selection. A shared enriched set of 113 CDR3-VH clonotypes was identified and displayed a defined physicochemical profile, including increased positive charge, recurrent aromatic residue patterns, constrained CDR3-VH length distribution, higher theoretical pI, and reduced hydrophobicity. Representative functional assays further supported the relevance of this signature: among the selected recombinant scFv clones, 12F2 showed preferential binding to both PS1-ASO and PS2-ASO, with reduced reactivity toward the phosphodiester-backbone oligonucleotide used as control. In ASO-treated cells, 12F2 produced a detectable intracellular signal after PS-ASO transfection, whereas PO-ASO-treated cells showed absent or nearly absent signal. Discussion: These results define an NGS-guided framework for identifying early-stage repertoire focusing and physicochemical signatures associated with recognition of modified nucleic acid backbones. The common property-level features suggest convergent binding solutions compatible with recognition of phosphorothioate-associated molecular features, supporting the rational prioritization of candidate binders against challenging polyanionic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.